Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Human coronaviruses need organic materials to transfer efficiently between surfaces

This study, published in the journal Viruses, indicated that human coronaviruses do not transfer effectively from contaminated hands to contact surfaces without the presence of any organic material.

21 Jul 2021

Scientists explore susceptibility of different animals to SARS-CoV-2 infection

A team of researchers at the Institute of Infectious Diseases (IFIK) at the University of Bern and the Institute of Virology and Immunology (IVI) has utilized a unique collection of advanced cell culture models of cells lining the airways from various domesticated and wildlife animals. This way, the team can determine which animals are susceptible to SARS-CoV-2 infection.

20 Jul 2021

Potent nasal vaccine protects non-human primates from SARS-CoV-2

A team of US-based scientists has recently demonstrated the efficacy of a live attenuated, recombinant coronavirus disease 2019 (COVID-19) vaccine candidate currently under phase I clinical trial as a single-dose intranasal vaccine.

20 Jul 2021

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

Florida International University researchers have investigated the mutation-induced structural changes in the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could contribute to its immune evasion abilities.

20 Jul 2021

COVID-19 vaccination remains Australia's best option for a return to normal, say researchers

Researchers in Australia and the United States have advised that the recent decision in Australia to prioritize older vulnerable age groups for vaccination against coronavirus disease 2019 (COVID-19) represents the optimal strategy for reducing deaths caused by the disease.

20 Jul 2021

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Researchers in Canada have developed an adenoviral vector-based vaccine against coronavirus disease 2019 (COVID-19) that induced robust immune protection against the ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice.

20 Jul 2021

Researchers examine the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in reducing household transmission

A new study has been published on the medRxiv* preprint server, which focuses on the effectiveness of the BNT162b2 vaccine by studying the susceptibility of a vaccinated individual to infection. The researchers have also studied the effect of the vaccine on virus transmission.

20 Jul 2021

Study examines clinical outcomes in vaccinated individuals hospitalized with SARS-CoV-2 Delta variant

A new study has been published on the medRxiv* preprint server that has evaluated the clinical outcomes of the COVID-19 patients hospitalized in AIG hospitals, Hyderabad, India, between April 24, 2021, and May 31, 2021.

20 Jul 2021

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.

20 Jul 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

An interesting new study reports that vaccine hesitancy in the UK is driven not, as is commonly thought, by the so-called ‘infodemic’ of misinformation that has characterized much public messaging during the COVID-19 pandemic. Instead, the personality of the individual, the ability to trust scientific and government leadership, political affiliations, and openness relative to the process of vaccine development was found to be key in the development of this attitude.

20 Jul 2021

COVID-19 vaccination in New York City reduces hospital admissions and deaths

A new study, released as a preprint on the medRxiv* server, shows how the successful rollout of effective COVID-19 vaccines in this metropolis led to the dramatic reduction in the number of cases with moderate to severe coronavirus disease 2019 (COVID-19) and curbed COVID-19-related mortality.

20 Jul 2021

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

The ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 190 million cases worldwide. Of these, over 4 million have died due to the infection.

20 Jul 2021

How SARS-CoV-2 infects the brain

While there is no official explanation on how SARS-CoV-2 travels to the brain, a new review published in the journal Fluids and Barriers of the CNS concluded that there is insufficient evidence on COVID-induced neurological problems coming from a direct invasion of SARS-CoV-2 into the brain.

20 Jul 2021

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

A multinational research group has been the first to show the excellent activity of artemisinin-based treatment against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human cell lines – including a specific type of lung cells. Their findings were recently published in the journal Scientific Reports.

19 Jul 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Iodine derivative kills SARS-CoV-2 within 90 sec

A recent study estimated the virucidal efficacy of EID for oral/nasal decontamination of known or suspected cases of COVID-19.

19 Jul 2021

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

A new study evaluates the efficacy of vaccine- and infection-induced antibodies against SARS-CoV-2 variants.

19 Jul 2021

Study suggests children develop short-term humoral immunity following SARS-CoV-2 infection

A single-center, cross-sectional epidemiological survey conducted in Israel has recently pointed out that antibodies induced by natural SARS-CoV-2 infection in children start declining just after 4 months of acute infection. However, their seropositivity rates are not impacted by school reopening. The study has recently been published in the journal Acta Paediatrica.

19 Jul 2021

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

An interesting study led by scientists in the U.S. has recently revealed that the microbial community in the gut is directly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and that virus-mediated gut microbiome dysbiosis may cause severe secondary infections in coronavirus disease 2019 (COVID-19) patients. The study is currently available on the bioRxiv* preprint server.

19 Jul 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Human coronaviruses need organic materials to transfer efficiently between surfaces

Scientists explore susceptibility of different animals to SARS-CoV-2 infection

Potent nasal vaccine protects non-human primates from SARS-CoV-2

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

COVID-19 vaccination remains Australia's best option for a return to normal, say researchers

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Researchers examine the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in reducing household transmission

Study examines clinical outcomes in vaccinated individuals hospitalized with SARS-CoV-2 Delta variant

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

COVID-19 vaccination in New York City reduces hospital admissions and deaths

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

How SARS-CoV-2 infects the brain

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Iodine derivative kills SARS-CoV-2 within 90 sec

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

Study suggests children develop short-term humoral immunity following SARS-CoV-2 infection

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in